Asthma Control Test

Abstract

The Asthma Control Test (ACT) is an internationally recognized, patient-completed psychometric and clinical screening instrument engineered to evaluate multidimensional asthma control in individuals aged 12 years and older. Developed by Nathan, Sorkness, Kosinski, Schatz, Li, Marcus, Murray, and Pendergraft (2004) in collaboration with QualityMetric Incorporated, the ACT addresses a crucial gap in chronic respiratory disease management by translating complex symptomatic and functional manifestations into an interpretable metric for both clinicians and patients. The instrument consists of five categorical items evaluated over a 4-week recall window, capturing activity limitation, dyspnea (shortness of breath), nocturnal and early morning awakenings, rescue medication usage (short-acting beta-2 agonists), and self-rated overall asthma control.

Each item is scored on a 5-point categorical response scale ranging from 1 (representing the poorest control or maximal functional impairment) to 5 (indicating complete control or absence of impairment). Summed composite scores range from 5 to 25. A cut-off score of 19 or lower reliably identifies patients with poorly controlled asthma, whereas scores of 20 to 24 denote well-controlled asthma, and a score of 25 reflects complete control. Extensive psychometric evaluations demonstrate high internal consistency reliability (Cronbach’s alpha spanning 0.84 to 0.89) and excellent test-retest reproducibility (intraclass correlation coefficients ranging from 0.77 to 0.85). Criterion, construct, and longitudinal responsiveness analyses substantiate the tool’s capacity to reflect pulmonary function metrics (such as forced expiratory volume in one second, FEV₁), specialist clinical ratings, and meaningful therapeutic changes, with an established minimal clinically important difference (MCID) of 3 points. The ACT stands as a cornerstone patient-reported outcome (PRO) measure in contemporary respiratory medicine, health psychology, and clinical trials worldwide.

Keywords

Asthma Control Test, ACT, asthma control, patient-reported outcome, psychometrics, respiratory disease, clinical assessment, dyspnea, health-related quality of life, chronic disease management, spirometry, treatment responsiveness

Authors

The Asthma Control Test was established through a multidisciplinary consortium of clinical pulmonologists, allergists, and psychometric researchers. The foundational development and validation initiatives were spearheaded by:

• Robert A. Nathan, MD – Clinical Professor of Medicine, University of Colorado Health Sciences Center, and Asthma & Allergy Associates, Colorado Springs, Colorado, USA.
• Christine A. Sorkness, PharmD – Professor of Pharmacy and Medicine, School of Pharmacy and School of Medicine and Public Health, University of Wisconsin–Madison, Madison, Wisconsin, USA.
• Mark Kosinski, MA – Principal Scientist and Psychometrician, QualityMetric Incorporated, Lincoln, Rhode Island, USA.
• Michael Schatz, MD, MS – Department of Allergy, Kaiser Permanente Medical Center, San Diego, California, USA.
• James T. Li, MD, PhD – Division of Allergic Diseases, Mayo Clinic and Foundation, Rochester, Minnesota, USA.
• Pamela Marcus, MS – QualityMetric Incorporated, Lincoln, Rhode Island, USA.
• John J. Murray, MD, PhD – Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
• Tara B. Pendergraft, MPH – GlaxoSmithKline, Research Triangle Park, North Carolina, USA.

Additional developmental and childhood adaptation studies involve collaborating psychometricians and investigators, including Mark S. Bayliss, MSc, and Elizabeth W. Fortin, MS, who contributed significantly to the pediatric adaptations and cross-cultural scaling projects with QualityMetric Incorporated.

Purpose

Asthma is a chronic inflammatory disorder of the airways characterized by recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. Despite substantial pharmacological advances, widespread discrepancies persist between objective indices of physiological impairment and patients’ subjective perceptions of illness severity. The primary purpose of the Asthma Control Test is to bridge this translational divide by providing a standardized, brief, highly accessible instrument capable of quantifying the level of asthma control experienced during daily living.

Historically, routine clinical examinations disproportionately relied on sporadic physiological measures, such as peak expiratory flow (PEF) and spirometric FEV₁. While these biophysical markers capture airway caliber and pulmonary obstruction at a single time point, they correlate modestly with functional daily impairment, emotional distress, nocturnal waking, and emergency medication dependency. Consequently, clinical guidelines published by the Global Initiative for Asthma (GINA) and the National Asthma Education and Prevention Program (NAEPP) shifted the paradigm of management from classification of static disease severity to the ongoing longitudinal appraisal of dynamic asthma control. The ACT was systematically constructed to realize this guideline-directed focus.

In clinical practice, the ACT assists physicians, respiratory therapists, and specialized nurses in rapidly identifying patients experiencing sub-optimal control who may benefit from stepped-up controller therapy (e.g., inhaled corticosteroids, long-acting beta-agonists, or biologic interventions). Because patients often underreport chronic symptoms due to subconscious behavioral habituation—such as gradually reducing physical activity to avoid precipitating breathlessness—the structured inquiry of the ACT uncovers clinically actionable morbidity that standard open-ended medical interviews may overlook.

In health services research and clinical trials, the ACT serves as an essential primary or secondary endpoint. Its documented responsiveness to pharmacological regimens makes it an ideal instrument for evaluating the therapeutic efficacy of novel compounds, educational behavioral interventions, and telemedicine-based disease management platforms. Furthermore, the instrument empowers self-management: when patients complete the questionnaire prior to an appointment or via digital health portals, it fosters health literacy, heightens personal symptom vigilance, and provides an objective benchmark that anchors collaborative shared decision-making.

Psychological Construct

The Asthma Control Test quantifies the latent psychological and clinical construct of asthma control. Conceptually, asthma control comprises two distinct but interrelated clinical domains: current clinical control (the manifestations of disease present day-to-day) and future risk (the probability of adverse events, acute exacerbations, emergency interventions, accelerated lung function decline, or treatment side-effects). The ACT operates primarily as an index of current clinical control, translating behavioral limitations, nocturnal disruptions, affective self-evaluation, and physiological symptoms into a unidimensional metric.

1. Physical and Role-Function Impairment (Item 1)

Asthma frequently interferes with an individual’s ability to discharge daily occupational, educational, and domestic responsibilities. Item 1 interrogates the extent to which asthma symptoms prevented the patient from accomplishing typical demands at work, school, or home during the past 4 weeks. Psychologically, this domain taps into functional status, behavioral avoidance, and role disability. Individuals with uncontrolled illness experience micro-disabilities—such as taking longer breaks, delegating basic tasks, or abstaining from recreational pursuits—which erode self-concept, social participation, and professional productivity.

2. Daytime Symptom Burden: Dyspnea (Item 2)

Dyspnea, or breathlessness, represents one of the most frightening subjective experiences associated with respiratory illness, carrying significant affective and cognitive distress. Item 2 measures the precise frequency of shortness of breath over the assessment epoch. Chronic breathlessness stimulates sympathetic nervous system arousal and can trigger secondary anxiety, panic, and kinesiophobia (fear of movement). Tracking dyspnea frequency provides direct insight into how often the patient’s airway resistance reaches conscious, distressing thresholds.

3. Nocturnal Disruption and Sleep Architecture (Item 3)

Circadian fluctuations in bronchial caliber, parasympathetic tone, cortisol nadirs, and airway inflammation cause asthma symptoms to worsen during the night, a phenomenon known as nocturnal asthma. Item 3 captures sleep fragmentation driven by coughing, wheezing, breathlessness, or chest tightness. Nighttime awakenings carry severe secondary psychological consequences, including daytime somnolence, cognitive fatigue, executive dysfunction, irritability, and altered emotional regulation. Capturing sleep integrity is therefore vital to both physiological control and psychological well-being.

4. Pharmacological Dependence and Rescue Behavior (Item 4)

Reliever medication usage (e.g., short-acting beta-2 agonists such as albuterol/salbutamol) reflects acute symptom management behaviors. High rescue inhaler dependency signifies persistent, unsuppressed underlying airway inflammation and suboptimal maintenance therapy. In psychological terms, rescue inhaler use can function as an anxiety-reduction behavior or a conditioned coping mechanism, where patients lean on quick-relief bronchodilators to mitigate distressing sensations rather than adhering to scheduled anti-inflammatory regimens. Item 4 provides an objective proxy for disease instability via behavioral consumption metrics.

5. Metacognitive Appraisal of Disease Mastery (Item 5)

Item 5 asks patients to provide a global subjective appraisal of their overall asthma control over the preceding 4 weeks. This item captures metacognitive awareness, illness representations, and perceived control. Even when individual symptoms seem modest, a patient’s global rating synthesizes subjective vulnerability, fear of sudden exacerbation, and the psychological burden of living with a labile chronic illness. By integrating this self-appraisal alongside objective behavioral items, the ACT preserves the patient’s sovereign experiential voice.

Theoretical Framework

The Asthma Control Test is grounded in the intersection of psychometric measurement theory, health psychology, and contemporary chronic disease management frameworks. Historically, biomedical models conceptualized asthma as an episodic bronchospastic event, emphasizing acute physiological rescue. However, contemporary biopsychosocial paradigms, such as George Engel’s model and modern self-regulation frameworks, view chronic airway disease as a continuous state wherein physiological pathology interacts dynamically with cognitive perception, affective state, and health behaviors.

The Common-Sense Model of Self-Regulation

Howard Leventhal’s Common-Sense Model of Self-Regulation (CSM) provides an explanatory psychological framework for the ACT. The CSM posits that individuals confronted with illness form distinct cognitive and emotional representations across five dimensions: identity (symptoms experienced), timeline, consequences, cause, and control/cure. When patients experience breathlessness (Item 2) or nighttime awakenings (Item 3), their internal cognitive schema interprets these as somatic cues of impending danger, eliciting coping actions such as rescue inhaler use (Item 4) or behavioral withdrawal from occupational tasks (Item 1). Item 5 reflects the patient’s overarching self-regulatory appraisal of whether their behavioral and medical strategies successfully keep the disease in equilibrium.

Classical Test Theory and Scale Reduction Models

From a psychometric perspective, the ACT was developed using the rigorous principles of Classical Test Theory (CTT) combined with modern item reduction methodology. Nathan et al. (2004) initially culled a broad pool of 22 candidate items down to the most informative five items through step-wise multivariable logistic regression and discriminant function analysis. The goal was to maximize information yield while minimizing respondent burden. The resulting 5-item scale behaves as an efficient, highly sensitive composite index where each item represents an essential empirical indicator of the latent construct “asthma control.”

Validity

The validity of the Asthma Control Test has been evaluated and confirmed across numerous clinical trials, population cohorts, and linguistic settings, encompassing thousands of pediatric, adolescent, and adult patients.

Construct and Discriminant Validity

In the foundational validation study by Nathan et al. (2004), involving 466 patients with asthma managed in specialty respiratory clinics, the ACT exhibited robust construct validity. The scale effectively discriminated between groups of patients categorized by asthma specialists as having well-controlled, somewhat controlled, or poorly controlled asthma (ANOVA F = 138.8, p < 0.001). Patients deemed well-controlled by pulmonologists had significantly higher ACT mean scores (20.3) compared to those classified as poorly controlled (14.2). Discriminant validity was further reinforced by significant differences across physiological strata: patients with higher ACT scores demonstrated significantly higher percent-predicted FEV₁ values (r = 0.45 to 0.52, p < 0.001) compared to their uncontrolled counterparts.

Criterion and Concurrent Validity

Concurrent validity has been established through direct comparisons with legacy respiratory inventories, most notably Elizabeth Juniper’s Asthma Control Questionnaire (ACQ). Investigations comparing the ACT and the ACQ consistently reveal strong inverse correlations, with Pearson and Spearman correlation coefficients typically ranging between r = −0.82 and −0.89 (due to the opposite scoring directions: higher ACT indicates superior control, whereas higher ACQ indicates poorer control). Furthermore, the ACT correlates positively with disease-specific quality of life instruments, such as the Asthma Quality of Life Questionnaire (AQLQ), with coefficients typically exceeding 0.70.

Diagnostic Accuracy and Receiver Operating Characteristic (ROC) Analysis

A primary psychometric achievement of the ACT is its precise diagnostic classification capability. In ROC curve analyses using pulmonary specialist evaluation as the external gold standard, an ACT cutoff score of ≤19 yielded an Area Under the Curve (AUC) of 0.84 to 0.87. At the threshold of 19 or lower, the ACT demonstrates a sensitivity of 71.3% to 75.0% and a specificity of 71.4% to 82.0% for detecting inadequately controlled asthma. Subsequent large-scale general practice evaluations, such as the validation study conducted by Thomas et al. (2009), confirmed an AUC of 0.85 in primary care settings, confirming its generalizability outside tertiary specialist environments.

Longitudinal Responsiveness and Minimal Important Difference

Schatz et al. (2006, 2007) examined the longitudinal responsiveness of the ACT across multiple time points. When patients underwent clinical improvements or deteriorations—as evidenced by specialist rating shifts and FEV₁ alterations following therapy escalation or tapering—the ACT exhibited marked sensitivity to change (effect sizes > 0.80). Utilizing both anchor-based and distribution-based psychometric methods, Schatz et al. established that a 3-point change in the total ACT score represents the Minimal Clinically Important Difference (MCID). A change of 3 or more points denotes a clinically meaningful shift in health status, providing clinicians and researchers with an empirical benchmark for determining treatment efficacy.

Reliability

The Asthma Control Test demonstrates high reliability across diverse demographic cohorts, clinical environments, and administration formats (including paper-and-pencil, digital portals, and telephone interviews).

Internal Consistency

In the initial validation cohort by Nathan et al. (2004), the internal consistency reliability of the 5-item ACT yielded a Cronbach’s alpha of 0.84. In a subsequent confirmatory study by Schatz et al. (2006) involving 1,113 asthmatic patients cared for in managed care organizations, Cronbach’s alpha reached 0.85. Cross-cultural adaptation studies across Spanish, Chinese, French, German, Italian, and Arabic cohorts have mirrored these findings, consistently reporting alpha coefficients ranging between 0.82 and 0.89. These statistics confirm that the five items possess high internal homogeneity while remaining free of redundant, multicollinear overlap.

Test-Retest Reliability

Test-retest stability was evaluated among clinically stable patients who demonstrated no change in their pulmonary status or specialist ratings between evaluations spaced 4 to 14 days apart. The intraclass correlation coefficient (ICC) across these stable cohorts ranged from 0.77 to 0.85, reflecting exceptional reproducibility. Item-by-item weighted kappa coefficients ranged from 0.62 to 0.79, demonstrating that individual symptom domains exhibit solid stability when disease state remains static.

Factor Analysis

The latent dimensionality of the ACT has been subjected to rigorous exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) across diverse international populations.

Exploratory Factor Analysis (EFA)

Initial exploratory factor analyses conducted during scale derivation revealed an unambiguous, unidimensional factor structure. Principal components analysis and common factor analysis extracted a single dominant eigenvalue (> 2.8), explaining over 58% to 65% of the total shared variance among the items. Scree plot analyses consistently present a sharp drop-off after the first factor, confirming the absence of meaningful secondary factors.

Confirmatory Factor Analysis (CFA)

Confirmatory factor analytic investigations evaluating the single-factor model have demonstrated robust goodness-of-fit indices across published literature. Representative CFA results from large clinical populations indicate:

• Comparative Fit Index (CFI): 0.97 to 0.99 (exceeding the standard 0.95 criterion for exemplary model fit).
• Tucker-Lewis Index (TLI): 0.96 to 0.98.
• Root Mean Square Error of Approximation (RMSEA): 0.042 to 0.058 (with 90% confidence intervals remaining below the 0.08 benchmark of acceptable approximation error).
• Standardized Root Mean Square Residual (SRMR): 0.024 to 0.035.

Standardized Factor Loadings

Standardized factor loadings from CFA evaluations consistently reveal robust item-to-construct correlations, with all parameters achieving statistical significance at p < 0.001:

• Item 1 (Activity / Work Limitation): Loadings typically range between 0.68 and 0.76.
• Item 2 (Shortness of Breath): Loadings typically range between 0.77 and 0.84.
• Item 3 (Nighttime Awakenings): Loadings typically range between 0.65 and 0.73.
• Item 4 (Rescue Inhaler Use): Loadings typically range between 0.69 and 0.78.
• Item 5 (Self-Rated Control): Loadings typically range between 0.78 and 0.86.

The high loadings observed across all five items confirm that each variable contributes substantial shared variance to the overarching construct of clinical asthma control, validating the practice of summing all five item scores into a singular unidimensional index.

Instrument / Measurement Tool

• Instrument Name: Asthma Control Test (ACT)
• Instrument Type: Self-administered Patient-Reported Outcome (PRO) questionnaire
• Target Population: Individuals aged 12 years and older diagnosed with bronchial asthma (for pediatric patients aged 4 to 11 years, the separate Childhood Asthma Control Test [C-ACT] is utilized)
• Administration Format: Paper-and-pencil questionnaire, digital tablet, mobile clinical application, or clinician-facilitated interview
• Recall Period: Past 4 weeks
• Item Count: 5 items
• Response Scale: 5-point categorical response scale (1 to 5, where 1 indicates the poorest control/highest impairment and 5 indicates complete control/no impairment)
• Scoring Procedure: Sum the raw numerical scores obtained across all 5 items. The total sum yields an overall score ranging from 5 to 25.
• Score Interpretation:
  • Score of 25: Asthma is completely controlled. The patient reports zero activity limitations, absence of dyspnea, no nocturnal awakenings, no rescue medication use, and self-identifies as completely controlled.
  • Scores of 20 to 24: Asthma is well controlled. The patient experiences minimal symptoms and is generally meeting clinical treatment objectives.
  • Scores of 19 or below: Asthma may not be well controlled. This indicates inadequate disease management and represents an actionable clinical flag indicating the need for treatment escalation, evaluation of inhaler technique, appraisal of environmental triggers, or medication adherence counseling.
• Minimal Clinically Important Difference (MCID): 3 points

Permissions & Fee and Test Year

The Asthma Control Test was first published in 2004 by Nathan and colleagues in the Journal of Allergy and Clinical Immunology. The ACT is a copyrighted instrument developed by QualityMetric Incorporated in collaboration with medical advisors and supported by GlaxoSmithKline (GSK).

Licensing and Usage Conditions:

• Routine Clinical Practice: Healthcare professionals are generally permitted to use the standard paper-based questionnaire in routine individual clinical consultations, point-of-care clinic visits, and non-commercial educational contexts free of royalty fees. Many healthcare organizations integrate the 5-item scale directly into clinical flowsheets and patient intake portals.
• Funded Research & Clinical Trials: For sponsored clinical research studies, international epidemiological programs, or commercial software/telehealth integrations, formal licensing, permission agreements, and user fees are administered through QualityMetric Incorporated (Lincoln, RI, USA) or its designated distributors.
• Digital Implementations: Translating the instrument into proprietary electronic patient-reported outcome (ePRO) platforms, software medical devices, or public web interfaces requires verification of formatting fidelity and formal permission from the copyright holder.

References

• Nathan, R. A., Sorkness, C. A., Kosinski, M., Schatz, M., Li, J. T., Marcus, P., Murray, J. J., & Pendergraft, T. B. (2004). Development of the asthma control test: A survey for assessing asthma control. Journal of Allergy and Clinical Immunology, 113(1), 59–65. https://doi.org/10.1016/j.jaci.2003.09.008
• Schatz, M., Sorkness, C. A., Li, J. T., Marcus, P., Murray, J. J., Nathan, R. A., Kosinski, M., Pendergraft, T. B., & Jhingran, P. (2006). Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists. Journal of Allergy and Clinical Immunology, 117(3), 549–556. https://doi.org/10.1016/j.jaci.2006.01.011
• Schatz, M., Kosinski, M., Yarlas, A. S., Hanlon, J., Watson, M. E., & Jhingran, P. (2007). The minimally important difference of the Asthma Control Test. Journal of Allergy and Clinical Immunology, 120(4), 785–789. https://doi.org/10.1016/j.jaci.2007.07.008
• Thomas, M., Kay, S., Pike, J., Williams, A., Rosenzweig, J. R., Hillyer, E. V., & Price, D. (2009). The Asthma Control Test (ACT) as a predictor of GINA-defined asthma control: Analysis of a multinational study. Primary Care Respiratory Journal, 18(1), 41–49. https://doi.org/10.4104/pcrj.2009.00010
• Global Initiative for Asthma (GINA). (2023). Global Strategy for Asthma Management and Prevention. Available from: https://ginasthma.org/
• Juniper, E. F., O’Byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999). Development and validation of a questionnaire to measure asthma control. European Respiratory Journal, 14(4), 902–907. https://doi.org/10.1034/j.1399-3003.1999.14d29.x

13. Items of the Scale (Questionnaire)